

"We are thrilled to be part of the flourishing life sciences community in Toronto and to contribute to Ontario's vision



to help drive the province toward becoming a world leader in innovation for health and wellness. Canada's startup scene is booming, and we look forward to working with the many enterprising innovators in the region that are working with the aim to turn science into tangible commercial products."

- Melinda Richter,

Global Head of Johnson & Johnson Innovation, JLABS

Johnson & Johnson has been creating value through innovation for more than 130 years.

250+ Operating Companies

130 K + Employees Worldwide

175 +

Countries

Consumer Health Medical Devices Pharmaceuticals

Sectors



Johnson Johnson innovation

Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating potential healthcare solutions that aim to improve peoples' lives around the world. We work side by side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success. Our mission is to create the leading global innovation network to generate transformational healthcare solutions through value-creating collaborations & partnerships.

A great idea can come from anywhere.

Johnson Johnson innovation





Global Johnson & Johnson Innovation Network 2020



Johnson Johnson Innovation JLABS

We value great ideas and are passionate about removing obstacles to success to help innovators **unleash the potential** of their early scientific discoveries.

Benefits of JLABS

The leading co-working space for life science innovators and emerging companies.



Maintain complete control of your intellectual property



Provide direct pathway to early stage science investors



Access to entrepreneurial programs



Optimize research and development and prepare for commercialization



Introduce innovators to vital industry connections



Mentors and on-site advocates



Builds local and national partnerships



Access to partnering with Johnson & Johnson Innovation

Providing Small Companies With Big Company Benefits



ELITE. EXCLUSIVE. EXPOSURE.

Streamlined vendor selection process offers special services, pricing, and solutions geared specifically for life sciences entrepreneurs so they can focus on their science while getting the services and resources they need to succeed.



UNLOCK UNLIMITED POTENTIAL.

Connecting innovators and emerging companies with high-value healthcare investors around the globe focused on early-stage science who can help craft their pitch to secure funding.



EXPERTISE AT YOUR FINGERTIPS

Pairing The Johnson & Johnson Family of Companies mentors with emerging companies tailored to their specific needs and focus area to help maneuver around obstacles and accelerate growth.

NAVIGAT PR

CREATE. CONNECT. COLLABORATE.

Showcasing JLABS companies worldwide to help build cross-collaboration for greater success. Tracks and measures JLABS companies and the real-time landscape.

A Model of Proven Success

You're in good company. Innovators and emerging companies working at JLABS have successfully struck deals with major companies and organizations around the world.

AbbVie Amgen Atlas Venture

ARCH Venture Partners

Bayer

Bristol Myers Squibb

Celgene

Draper Fisher Jurvetson

Google Ventures

Illumina

The Johnson &

Johnson Family of

Companies

Kleiner Perkins

Merck

MRM

Novartis

OrbiMed

Pfizer

Polaris Partners

SchindlerAM

Sofinnova

SR One

Third Rock Ventures

Versant Ventures

\$42.1B Financing and **Strategic Relationships**

(Secured and Contingent)

Companies Acquired

Elite Collaboration Opportunities

58% First-time Entrepreneurs

42% Serial Entrepreneurs

30% Female-Led

30% Minority-Led

Exclusive Access to 695+ Companies

Pharmaceuticals

Medical Devices

Consumer

Cross-Sector

Exposure to High-Value Clients

142

Publicly Offered

JI ABS companies with a deal with The Johnson & Johnson Family of Companies



JLABS @ Toronto Overview

Johnson Johnson Innovation JLABS

Our Mission at JLABS @ Toronto

Help biotech
companies grow
& scale through
key resources
and physical
space to drive
commercialization.

Facilitate
collaborations
& financing
through our
expansive network.

Drive engagement
between The
Johnson & Johnson
Family of Companies
and Canadian biotechicompanies.

Support the growth of the biotech ecosystem in Toronto and in Canada.



Launched in May 2016, Toronto was the sixth JLABS site out of the now 13 locations across the globe. It was also the first JLABS location outside the United States.

JLABS @ Toronto Companies

Sectors

Pharmaceuticals

Medical **Devices**

Consumer

Residents

Current Residents

> BLUE KNIGHT™

QuickFire Winners Challenge


Current & Alumni

First-time Entrepreneurs

Entrepreneurs

Female-led Companies

Minority-led Companies



Best-in-Class Workspace



40,000 sq ft workspace that can accommodate up to 50 startups




Over \$5M in state-of-the art lab instrumentation and equipment



Specialty laboratories, including cell culture, chemistry, prototyping, and common research laboratories



Private offices, shared and coworking office space, and meeting rooms




"JLABS was a complete offering for an incubator space equipment, investor/ partner network, programming, and mentoring. Other incubators only had some of these pieces, but JLABS had everything."

— Brent Stead, CEO
Specific Biologics



JLABS @ Toronto is ideally positioned in downtown Toronto within the MaRS Discovery District, North America's largest urban innovation hub aiming to attract the best and brightest talent in science and technology. Companies want to be a part of the JLABS movement—in addition to our location, startups apply to access our wealth of resources, and for our help in catalyzing research and development and commercialization initiatives. We aim to maintain an 80%-85% occupancy rate to help support companies to grow and scale.



General Applicants

QuickFire Challenge Applicants

Accepted Applicants

^{*}The number of applicants and acceptance rate have remained consistent.



A Flexible Model Where Scientists Can Focus on the Science

At JLABS @ Toronto, we value great ideas and are passionate about helping to remove obstacles. We provide innovators with mentors and on-site advocates with the aim to help remove barriers and accelerate science. Our state-of-the-art labs, equipment, and innovation centers enable emerging companies to thrive. JLABS has a goal to help companies navigate the complicated landscape of a healthcare startup by providing access to entrepreneurial programs and tools. We aim to enable emerging companies to develop their science while maintaining complete control of their intellectual property and decision-making—truly a "no strings attached" model.

RESIDENT SPOTLIGHT



Company Growth

3

>

11

Employees

Employees

Footprint Growth

1 Desk ▶ 1 Private Office & 1 Private Lab

Funding Growth

\$6M Raised In See Round (2019)

R&D Stage Advancement

Discovery ► Preclinical

"We couldn't have started without JLABS. We needed Cat 2 wet lab space—JLABS was the only viable solution. There are basically no other options here for small companies like us with loose university affiliations. We would have left Toronto without JLABS."

Sam Cooper, CEO and Co-Founder
 Phenomic Al

Providing the Resources Needed to Accelerate Growth

JLABS @ Toronto is part of the larger Johnson & Johnson Innovation family of companies and ecosystem, which can help to catalyze growth, connections, and success. We strike to help emerging companies remove hurdles to optimize R&D and prepare for commercialization. JLABS introduces innovators to vital industry connections and provides a direct pathway to early-stage science investors. We aim to help companies transform their scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. Over the past 5 years, JLABS @ Toronto has helped create 605 full-time and 244 part-time employees.

RESIDENT SPOTLIGHT



Company Growth

3



20

Employees

Employees

Deals & Partnerships

Confidential Funding Received & Agreements with Multiple Partners While Being in JLABS

Footprint Growth

2



3

Lab Benches

Private Labs

R&D Stage Advancement

Full Clinical Commercial

"Facilities, people, and name are some of the biggest benefits of JLABS. There's a significant lack of lab space for early-stage life sciences companies and what Johnson & Johnson Innovation has built within MaRS is quite impressive. In addition, being a resident of JLABS brings a certain respectability for any company—it signifies we're beyond the early stages of company formation & are investing in scientific research. The men and women who work at JLABS bring a human element that makes sure JLABS doesn't feel like a huge corporation."

Ted Jin, Founder & CEO Dose Biosystems

Attracting Great Companies Across Canada

JLABS @ Toronto has developed local, national, and international collaborations with academic institutions, hospitals, industry organizations, and foundations to further innovation. We've brought external and internal (The Johnson & Johnson Family of Companies) expertise to more than 15 cities across the country through educational programming, webinars, and speaking engagements. With approximately 43% of resident companies coming from outside the greater Toronto area, from places like Halifax, Vancouver, Montreal, and Calgary, JLABS has become a preferred home base for R&D and management teams due to our ability to help spur growth.

RESIDENT SPOTLIGHT

MEDIPHAGE BIOCEUTICALS

Company Growth

>

11

Employees

Employees

Footprint Growth

1 Desk & 1 Lab Bench ▶
1 Private Office & 5 Lab Benches

Funding Growth

\$3.25M

Raised In Seed Round

R&D Stage Advancement

Discovery Preclinical

"In addition to the top-notch facilities and equipment, access to talent, and being in the center of the city, JLABS' access to investors was a big driver to bringing our company from Waterloo to Toronto."

Lee Bowman, COOMediphage Bioceuticals

"Since joining JLABS @ Toronto, we have achieved many discovery milestones, including hit identification, Hit2Lead, lead optimization, and clinical candidate selection, enabling us to transition into a full preclinical development mode with CMC, toxicology and regulatory activities, moving forward towards Endogena Therapeutics' first-in-human clinical trial with our ophthalmology product for retinitis pigmentosa patients."

- Daphna Mokady, VP Discovery **Biology & Site Head Toronto Endogena Therapeutics**

Research & Development

59%

Of JLABS @ Toronto Residents Have Advanced Their R&D Programs While Within JLABS

The majority of movements are into:

Biomarkers

17.3%

Launching A Product

17.3%

Phase 1 or 2

17.3%

Early Technical Feasibility & Prototyping

15.3%





JLABS @ Toronto Alumni Spotlight

	Company Growth	Footprint Growth	Funding Growth	R&D Stage Advancement	Notable Patnership	
COR VISTA®	11▶30 Employees	1 Private Office ▶ 7 Private Offices & 1 Lab Bench	\$25M Series B Financing Raised while in JLABS \$100M total raised	Preclinical ► Clinical Studies	Research Funding Agreement with Actelion Pharmaceuticals Ltd (part of the Johnson & Johnson Family of Companies)	"Our deal with Actelion has resulted in several million dollars of sponsored research. The collaboration with Actelion has been huge for us." — Shyam Ramchandani, VP of R&D
©CYCLICA	15►50 Employees	N/A	\$40M Raised To Date \$23m Series B and \$4.65m Series A (Raised while at JLABS)	Discovery ▶ Platform Launch	Yuhan Pharmaceuticals • AUM Biosciences • Cerevel Therapeutics • Merck KGaA • Bayer • FMC	"The JPAL system was helpful for Cyclica, as it provided us direct feedback on our platform and the need for important prospective validation. This has been key to many of the strategic decisions we've made." — Naheed Kurji, Co-Founder, President, CEO
BlueRock Therapeutics	Employees	►4 Private Offices &	\$225M Series A Financing Raised Before JLABS	Preclinical ► Clinical Development	Acquired by Bayer in 2019	"We wouldn't have been able to maintain our rapid growth curve without JLABS, as our permanent facility was under construction and we lacked capacity to otherwise hire new employees."
		3 Lab Benches			:	— Michael Scott,

SVP Product Development



Facilitating Collaborations and Financing in and Around Toronto

Johnson Johnson Innovation

JLABS

Facilitating Collaborations to Drive Innovation

JLABS @ Toronto provides an experience beyond the bench for scientists and entrepreneurs. Our program aims to enable residents, alumni, and the innovation ecosystem to develop connections with our network of investors through our Investor Hub and through investor-related programs, one-on-one meetings, and networking events.

Global Investors Traveled to Canada for Meetings With Canadian Startups

965 One-On-One Meetings
Between Startups and
With Global Investors

JLABS @ Toronto Investor
Hub Members Come in
Monthly, Bi-Monthly, or
Quarterly to Host Office
Hours On-Site

JLABS @ Toronto Companies Have Successfully Secured Investments Through Participation With the On-Site Investor Hub in Just 1 Year

Global Investors Who Visited:

JJDC
Gates Foundation
Sofinnova
Novo Ventures
DCVC
Novartis Venture Fund

AbbVie Ventures Canaan Partners 5AM Ventures Khosla Ventures "My introduction to JLABS
@ Toronto was through the
Investor Hub as an investor,
where we funded three
companies. Based on that
success, when I decided to
start my own company,
I applied to JLABS."



— Drew Taylor, CEO
Acorn Biolabs


"As a direct result of the validating effect of being a JLABS @ Toronto resident, as well as the meetings and events organized by JLABS, we have been able to attract investors and partners to advance our technology."

Brent Stead, CEOSpecific Biologics


Overview of JLABS @ Toronto **Companies Deal & Funding Activity**



Deal Activity Overview



Funding Activity Overview



"The connections through JLABS @ Toronto have exceeded our expectations and been invaluable both with investors and networking with other JLABS companies.

Since moving to JLABS, we have received our NOL from Health Canada which means we can progress into Phase 1. We are also about to close a Series A.

A JLABS investor meeting in October 2017 resulted in a Series A investor who is committing \$500K."

— Mike Cooke, CEO AmacaThera



"The relationships I was able to forge with like-minded entrepreneurs in healthcare across

verticals within
JLABS @ Toronto and other sites
has enabled multiple
collaborations with other JLABS
companies, including with
NeuroTheryX, Mannin Research,
Translatum Medicus Inc, and
Rosetta Therapeutics."

— Naheed Kurji,
President and CEO
Cyclica






Experience Beyond the Bench

The JPALS program aims to provide JLABS @ Toronto resident companies with a forum to explore potential areas of collaboration within The Johnson & Johnson Family of Companies, as well as mentorship, coaching, and connections to support their growth.

Total Johnson & Johnson Family of Companies Visitors Over 5 Years



"Our company is working in a Johnson & Johnson Family of Companies relevant area (neurodegeneration)

and has secured a JPAL through the JLABS team. This resulted in our startup obtaining a small-molecule 'brain friendly' (Jump-StARter) screening library from Janssen Research & Development, LLC of over 80K chemical entities.

Peter Lewis, CEORosettaTherapeutics

RESIDENT SPOTLIGHT

PENTAVERE

"Our relationship with JLABS and The Johnson & Johnson Family of Companies has



helped accelerate the deployment of Pentavere's AI technology and deliver real value to clients and patients.

We have experienced over 500% revenue growth achieved since joining JLABS."

— Aaron Leibtag, CEO Pentavere **RESIDENT SPOTLIGHT**



WINTERLIGHT LABS

"Being in JLABS
@ Toronto added additional credibility and helped with discoverability. In August 2017, we were able to secure \$1M in venture capital while being in JLABS. Additionally, we did two deals with Janssen Research & Development, LLC, in December 2017 and December 2018. Those deals only happened because we were part of JLABS."

Liam Kaufman,CEO and Co-FounderWinterlight Labs

RESIDENT SPOTLIGHT

IMMUNE BI SOLUTIONS

"When our company became one of JLABS @ Toronto's first resident companies, we were connected with JPALS across The Johnson & Johnson Family of Companies, which culminated into an agreement with Janssen Biotech, Inc, to identify and develop therapeutic antibodies for multiple target areas, including cancer."

Our selection and support from JLABS allowed us to raise over \$3M in seed rounds."

— Frédéric Leduc, CEO Immune Biosolutions



BLUE KNIGHT

Anticipate. Activate. Amplify.

BLUE KNIGHT™ Collaboration.

BLUE KNIGHT™ aims to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases. JLABS @ Toronto has dedicated space for Blue Knight, a collaboration between Johnson & Johnson Innovation—JLABS and the Biomedical Advanced Research and Development Authority (BARDA).

"With the BLUE KNIGHT opportunity coming along, we can now try to advance our project quicker and in a more de-risked way. These are the experts, so we're flattered that we could be part of this and that they're recognizing that we have elements of our technologies that are going to be useful in their programs."

— Brent Stead, CEO
Specific Biologics

"At JLABS @ Toronto, we put a point of focus on diversity, in both the programming and environment we create."



— Allan Miranda, Regional Head JLABS @ Toronto



"JLABS has continuously contributed to the life sciences ecosystem by fostering community-building through events, investor intros, and other networking opportunities."

— Ted Jin, Founder & CEO
Dose Biosystems

Driving the Region's Culture of Entrepreneurism

Since opening, JLABS @ Toronto has been the leader of life sciences education for the city, and a centerpiece of Toronto's innovation ecosystem. Attracting leading experts and researchers across healthcare sectors, our programs have benefited and grown the life sciences community through workshops, panel discussions, investor meeting opportunities, scientific presentations, and networking events.

5 Years of JLABS @ Toronto Programming

358 Educational Programs
Across 3 Major Sectors
of Healthcare

25,764

Event Attendees, 5,882 of Whom Were Our Own JLABS Residents

Artificial Intelligence
Events Hosted

Gell & Gene Therapy
Events Hosted

Events Hosted for Our Ecosystem Peers

Event Collaborations with MaRS, TIAP, OICR, CCRM, UofT & more!

Key Program Topics:

Artificial Intelligence, Cell & Gene Therapy, Neuroscience, Oncology, Infectious Diseases, Robotics, Consumer Health Commercialization, Investment Tips, and More

JLABS @ Toronto is powered by an engine of leaders who are truly second to none and are committed to ensuring this initiative succeeds.

Partners

Johnson & Johnson Innovation The University of Toronto MaRS Discovery District Janssen Canada Toronto Innovation Acceleration Partners (TIAP) Government of Ontario

Surrounding Healthcare Ecosystem

Centre for Addiction and Mental Health The Hospital for Sick Children Sinai Health System St. Michael's Hospital Sunnybrook Health Sciences Centre University Health Network



